The global non-invasive prenatal testing (NIPT) market size was estimated to be USD 14.76 billion in 2023 and is expected to reach at USD 35.18 billion by 2033 with a CAGR of 11.82% during the forecast period 2023-2033. The market is expanding as a result of factors such as rising demand for early and non-invasive fetal diagnostics, favorable reimbursement policies, and an increase in the number of infants born with chromosomal problems as a result of more late pregnancies. It is also anticipated that the rise in stillbirth instances would present a sizable potential opportunity for early disease diagnosis.
Increase in number of stillbirth cases is predicted to fuel the market growth during the forecast period. For instance, a study published in the National Library of Medicine in April 2023 found that between 0.4 and 0.9% of babies have chromosomal anomalies and that roughly half of these children have an aberrant phenotype. The third most frequent autosomal trisomy affects approximately 1 in 5000 to 1 in 16000 live births, according to the same source. Thus, with such stillbirths, the demand for testing rises, which is then anticipated to support the growth of the market across all segments throughout the forecast period.
By Product, Consumables was the highest revenue-grossing segment in the global biochip market in 2022 owing to the presence of major players offering a wide range of consumables for NIPT. Additionally, PCR instruments is predicted to grow at a fastest CAGR during the forecast period owing to continuous efforts undertaken by instrument manufacturers to develop advanced platforms. For instance, in August 2022, The first digital PCR apparatus is a product of Roche called the Digital LightCycler System. The purpose of this system is to assist clinical researchers in gaining a deeper understanding of a patient's cancer, genetic disease, or infection.
By Method, Cell-free DNA in Material Plasma Tests was the highest revenue-grossing segment in the global biochip market in 2022 owing to increasing technological advancements and surge in initiatives by market players for the development of new products. Additionally, ultrasound detection is predicted to grow at fastest CAGR during the forecast period owing to the surge in demand for cutting-edge technologies and 3D-4D imaging have improved real-time monitoring, safety, and efficiency of the test. For instance, in May 2022, GE Healthcare, a subsidiary of General Electric Company, has made a substantial investment of approximately USD 50 million in Pulsenmore, an Israeli startup. This investment enables expectant parents to monitor and track their pregnancies from the comfort of their own homes, including the ability to conduct self-scans.
By Application, Trisomy was the highest revenue-grossing segment in the global biochip market in 2022 owing to growing prevalence of chromosomal abnormalities and rising maternal age. Additionally, Microdeletion Syndrome is predicted to grow at fastest CAGR during the forecast period owing to increasing demand for non-invasive tests and rising technological advancements. For instance, in August 2022, the panoramic non-invasive prenatal test (NIPT) has been pre-submitted by Natera Inc. via the Q-Sub procedure to the Food and Drug Administration (FDA). The business submitted the pre-submission in June 2022, concentrating on identifying fetal chromosomal aneuploidies and the 22q11.2 deletion syndrome.
By End-user, Diagnostic Laboratories was the highest revenue-grossing segment in the global biochip market in 2022 owing to the growing incidence of chromosomal abnormalities, increasing initiatives to provide safe & effective prenatal tests, presence of a large number of diagnostic laboratories that offer NIPT, and the presence of key market players. For instance, in September 2022, Yourgene Health plc has obtained approval from the Health Sciences Authority (HSA) in Singapore for its IONA® Nx NIPT Workflow. This approval permits clinical laboratories to utilize the prenatal screening workflow, offering them a comprehensive and efficient testing solution to establish their own NIPT service. The workflow is fully automated, cost-effective, and ensures fast, accurate, and quality-assured results. Additionally, hospitals is predicted to grow at fastest CAGR during the forecast period owing to the increase in number of public and private hospitals that offer NIPT across the globe and surge in research & development activities in hospitals.
North America region is anticipated to witness the highest revenue share during the forecast period owing to the increasing diagnosis rates, growing awareness among the people, and surge in launch of advanced tests. For instance, in May 2021, Yourgene has introduced IONA Care, a service for non-invasive prenatal testing (NIPT) that enables the assessment of sex chromosome aneuploidies (SCA) and autosomal aneuploidies (AA) in pregnant women. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to growing development of healthcare infrastructure, surge in awareness programs, increasing focus on expansion by market players, and surge in mergers & acquisitions by leading market players. For instance, in July 2022, Genetic Technologies Limited has completed the acquisition of EasyDNA as part of its expansion efforts to offer Carrier Testing and Non-Invasive Prenatal Tests (NIPT) on its websites in Europe. Additionally, the company's Indian team has formed partnerships with stud farms to establish the lineage of horses through equine chain of custody identification.
Increase in number of stillbirth cases is predicted to fuel the market growth during the forecast period. For instance, a study published in the National Library of Medicine in April 2023 found that between 0.4 and 0.9% of babies have chromosomal anomalies and that roughly half of these children have an aberrant phenotype. The third most frequent autosomal trisomy affects approximately 1 in 5000 to 1 in 16000 live births, according to the same source. Thus, with such stillbirths, the demand for testing rises, which is then anticipated to support the growth of the market across all segments throughout the forecast period.
By Product, Consumables was the highest revenue-grossing segment in the global biochip market in 2022 owing to the presence of major players offering a wide range of consumables for NIPT. Additionally, PCR instruments is predicted to grow at a fastest CAGR during the forecast period owing to continuous efforts undertaken by instrument manufacturers to develop advanced platforms. For instance, in August 2022, The first digital PCR apparatus is a product of Roche called the Digital LightCycler System. The purpose of this system is to assist clinical researchers in gaining a deeper understanding of a patient's cancer, genetic disease, or infection.
By Method, Cell-free DNA in Material Plasma Tests was the highest revenue-grossing segment in the global biochip market in 2022 owing to increasing technological advancements and surge in initiatives by market players for the development of new products. Additionally, ultrasound detection is predicted to grow at fastest CAGR during the forecast period owing to the surge in demand for cutting-edge technologies and 3D-4D imaging have improved real-time monitoring, safety, and efficiency of the test. For instance, in May 2022, GE Healthcare, a subsidiary of General Electric Company, has made a substantial investment of approximately USD 50 million in Pulsenmore, an Israeli startup. This investment enables expectant parents to monitor and track their pregnancies from the comfort of their own homes, including the ability to conduct self-scans.
By Application, Trisomy was the highest revenue-grossing segment in the global biochip market in 2022 owing to growing prevalence of chromosomal abnormalities and rising maternal age. Additionally, Microdeletion Syndrome is predicted to grow at fastest CAGR during the forecast period owing to increasing demand for non-invasive tests and rising technological advancements. For instance, in August 2022, the panoramic non-invasive prenatal test (NIPT) has been pre-submitted by Natera Inc. via the Q-Sub procedure to the Food and Drug Administration (FDA). The business submitted the pre-submission in June 2022, concentrating on identifying fetal chromosomal aneuploidies and the 22q11.2 deletion syndrome.
By End-user, Diagnostic Laboratories was the highest revenue-grossing segment in the global biochip market in 2022 owing to the growing incidence of chromosomal abnormalities, increasing initiatives to provide safe & effective prenatal tests, presence of a large number of diagnostic laboratories that offer NIPT, and the presence of key market players. For instance, in September 2022, Yourgene Health plc has obtained approval from the Health Sciences Authority (HSA) in Singapore for its IONA® Nx NIPT Workflow. This approval permits clinical laboratories to utilize the prenatal screening workflow, offering them a comprehensive and efficient testing solution to establish their own NIPT service. The workflow is fully automated, cost-effective, and ensures fast, accurate, and quality-assured results. Additionally, hospitals is predicted to grow at fastest CAGR during the forecast period owing to the increase in number of public and private hospitals that offer NIPT across the globe and surge in research & development activities in hospitals.
North America region is anticipated to witness the highest revenue share during the forecast period owing to the increasing diagnosis rates, growing awareness among the people, and surge in launch of advanced tests. For instance, in May 2021, Yourgene has introduced IONA Care, a service for non-invasive prenatal testing (NIPT) that enables the assessment of sex chromosome aneuploidies (SCA) and autosomal aneuploidies (AA) in pregnant women. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to growing development of healthcare infrastructure, surge in awareness programs, increasing focus on expansion by market players, and surge in mergers & acquisitions by leading market players. For instance, in July 2022, Genetic Technologies Limited has completed the acquisition of EasyDNA as part of its expansion efforts to offer Carrier Testing and Non-Invasive Prenatal Tests (NIPT) on its websites in Europe. Additionally, the company's Indian team has formed partnerships with stud farms to establish the lineage of horses through equine chain of custody identification.
Segmentation: Non-Invasive Prenatal Testing (NIPT) Market Report 2022-2033
Non-Invasive Prenatal Testing (NIPT) Market Analysis & Forecast By Product 2022-2033 (Revenue USD Bn)
- Consumables
- Instruments
- Products
- Microarrays
- Assay Kits & Reagent
- NGS Systems
- Disposables
- PCR Instruments
- Ultrasound Devices
- Services
Non-Invasive Prenatal Testing (NIPT) Market Analysis & Forecast By Method 2022-2033 (Revenue USD Bn)
- Biochemical Screening Tests
- Ultrasound Detection
- Cell-free DNA in Material Plasma Tests
Non-Invasive Prenatal Testing (NIPT) Market Analysis & Forecast By Application 2022-2033 (Revenue USD Bn)
- Microdeletion Syndrome
- Trisomy
Non-Invasive Prenatal Testing (NIPT) Market Analysis & Forecast By End-user 2022-2033 (Revenue USD Bn)
- Hospitals
- Diagnostic Laboratories
Non-Invasive Prenatal Testing (NIPT) Market Analysis & Forecast by Region 2022-2033 (Revenue USD Bn)
North America
- U.S
- Canada
Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Non-Invasive Prenatal Testing (NIPT) Market: Product Estimates & Trend Analysis
8. Non-Invasive Prenatal Testing (NIPT) Market: Method Estimates & Trend Analysis
9. Non-Invasive Prenatal Testing (NIPT) Market: Application Estimates & Trend Analysis
10. Non-Invasive Prenatal Testing (NIPT) Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Non-Invasive Prenatal Testing (NIPT) Market
13. Europe Global Non-Invasive Prenatal Testing (NIPT) Market
14. Asia Pacific Global Non-Invasive Prenatal Testing (NIPT) Market
15. Latin America Global Non-Invasive Prenatal Testing (NIPT) Market
16. MEA Global Non-Invasive Prenatal Testing (NIPT) Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Genesis Genetics (CooperSurgical; Inc.)
- Natera Inc
- Centogene N.V.
- Illumina Inc
- Eurofins
- LifeCodexx GmbH
- MedGenome Labs Ltd
- F. Hoffmann-La Roche Ltd
- Myriad Women’s Health Inc.
- QIAGEN
- Laboratory Corp. of America Holdings
- Progenity Inc
- Quest Diagnostics Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 145 |
| Published | July 2023 |
| Forecast Period | 2022 - 2033 |
| Estimated Market Value ( USD | $ 14.76 Billion |
| Forecasted Market Value ( USD | $ 42 Billion |
| Compound Annual Growth Rate | 10.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 13 |
